卡铂-话题@MedSci

#卡铂#

64篇内容 | 2714人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1396292, encodeId=451f13962925c, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Natl Cancer Inst：TNBC：新辅助蛋白结合型紫杉醇+卡铂vs蛋白结合型紫杉醇+吉西他滨, objectType=article, longId=144214, objectId=35ae14421406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35ae14421406, replyNumber=0, likeNumber=90, createdTime=2018-07-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35ae14421406, moduleTitle=J Natl Cancer Inst：TNBC：新辅助蛋白结合型紫杉醇+卡铂vs蛋白结合型紫杉醇+吉西他滨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35ae14421406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396291, encodeId=f19a1396291d1, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, objectType=article, longId=139686, objectId=ff45139686f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff45139686f9, replyNumber=0, likeNumber=69, createdTime=2018-06-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff45139686f9, moduleTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff45139686f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396290, encodeId=caca139629046, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, objectType=article, longId=137196, objectId=7db713e1967a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db713e1967a, replyNumber=0, likeNumber=74, createdTime=2018-05-05, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db713e1967a, moduleTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db713e1967a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396289, encodeId=d2231396289aa, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=CLIN CANCER RES：新辅助卡铂和多西他赛治疗的三阴性乳腺癌患者的病理缓解情况, objectType=article, longId=136502, objectId=919713650250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=919713650250, replyNumber=0, likeNumber=66, createdTime=2018-04-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=919713650250, moduleTitle=CLIN CANCER RES：新辅助卡铂和多西他赛治疗的三阴性乳腺癌患者的病理缓解情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=919713650250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396288, encodeId=be67139628817, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：卡铂-紫杉醇 vs 卡铂-紫杉醇-曲妥珠单抗治疗子宫浆液性癌, objectType=article, longId=133724, objectId=4a7d133e24be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7d133e24be, replyNumber=0, likeNumber=65, createdTime=2018-03-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7d133e24be, moduleTitle=JCO：卡铂-紫杉醇 vs 卡铂-紫杉醇-曲妥珠单抗治疗子宫浆液性癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7d133e24be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396287, encodeId=4973139628e31, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lung Cancer：氨柔比星/卡铂+培非格司亭治疗广泛期SCLC, objectType=article, longId=129978, objectId=8b231299e833, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b231299e833, replyNumber=0, likeNumber=94, createdTime=2018-02-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b231299e833, moduleTitle=Lung Cancer：氨柔比星/卡铂+培非格司亭治疗广泛期SCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b231299e833)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396286, encodeId=24671396286f8, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, objectType=article, longId=124106, objectId=bed9124106d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed9124106d6, replyNumber=0, likeNumber=102, createdTime=2017-12-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed9124106d6, moduleTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed9124106d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396285, encodeId=1f69139628506, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=PLos One：使用顺铂 vs.卡铂治疗肺癌的血栓栓塞风险比较, objectType=article, longId=123185, objectId=82c2123185a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c2123185a0, replyNumber=0, likeNumber=79, createdTime=2017-12-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c2123185a0, moduleTitle=PLos One：使用顺铂 vs.卡铂治疗肺癌的血栓栓塞风险比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c2123185a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396284, encodeId=cfb2139628459, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。, objectType=article, longId=121373, objectId=6a6c1213e360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a6c1213e360, replyNumber=0, likeNumber=70, createdTime=2017-11-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a6c1213e360, moduleTitle=Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6c1213e360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396283, encodeId=b3b41396283e7, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：伊匹单抗联合紫杉醇和卡铂治疗晚期非小细胞肺癌, objectType=article, longId=111507, objectId=31d211150e7c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31d211150e7c, replyNumber=0, likeNumber=55, createdTime=2017-09-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31d211150e7c, moduleTitle=JCO：伊匹单抗联合紫杉醇和卡铂治疗晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31d211150e7c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396282, encodeId=b1d913962821a, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, objectType=article, longId=102825, objectId=3eb2102825e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb2102825e6, replyNumber=0, likeNumber=62, createdTime=2017-06-23, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb2102825e6, moduleTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb2102825e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396281, encodeId=7ec61396281f6, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J CLIN ONCOL：Palifosfamide联合卡铂或依托泊苷治疗小细胞肺癌的效果研究, objectType=article, longId=102142, objectId=39df10214292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39df10214292, replyNumber=0, likeNumber=83, createdTime=2017-06-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39df10214292, moduleTitle=J CLIN ONCOL：Palifosfamide联合卡铂或依托泊苷治疗小细胞肺癌的效果研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39df10214292)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396280, encodeId=146c13962808f, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：帕利伐米加入卡铂联合依托泊苷治疗中不能改善转移性小细胞肺癌患者的生存, objectType=article, longId=102075, objectId=6c081020e5bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c081020e5bc, replyNumber=0, likeNumber=88, createdTime=2017-06-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c081020e5bc, moduleTitle=JCO：帕利伐米加入卡铂联合依托泊苷治疗中不能改善转移性小细胞肺癌患者的生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c081020e5bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396279, encodeId=891d13962e9f0, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=J Clin Oncol：精原细胞瘤复发----卡铂辅助治疗疗效如何？, objectType=article, longId=95495, objectId=931395495a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=931395495a9, replyNumber=0, likeNumber=72, createdTime=2017-04-13, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=931395495a9, moduleTitle=J Clin Oncol：精原细胞瘤复发----卡铂辅助治疗疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=931395495a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396278, encodeId=8c2413962e8ca, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：男性临床I期精原细胞癌卡铂辅助化疗后复发状况调查, objectType=article, longId=83364, objectId=5933833646a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5933833646a, replyNumber=0, likeNumber=69, createdTime=2016-12-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5933833646a, moduleTitle=JCO：男性临床I期精原细胞癌卡铂辅助化疗后复发状况调查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5933833646a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396277, encodeId=91da13962e72b, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS, objectType=article, longId=79863, objectId=3fa9e98630a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fa9e98630a, replyNumber=0, likeNumber=37, createdTime=2016-10-13, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fa9e98630a, moduleTitle=ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fa9e98630a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396276, encodeId=c31613962e6b0, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=JCO：伊立替康+顺铂 vs 紫杉醇+卡铂一线治疗卵巢透明细胞癌(JGOG3017/GCIG 试验III期), objectType=article, longId=73685, objectId=920ee368569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920ee368569, replyNumber=0, likeNumber=81, createdTime=2016-07-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920ee368569, moduleTitle=JCO：伊立替康+顺铂 vs 紫杉醇+卡铂一线治疗卵巢透明细胞癌(JGOG3017/GCIG 试验III期), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920ee368569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396275, encodeId=041313962e503, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好, objectType=article, longId=72400, objectId=4e9ce240078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e9ce240078, replyNumber=0, likeNumber=74, createdTime=2016-07-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e9ce240078, moduleTitle=NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e9ce240078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396274, encodeId=741c13962e4ed, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=招募患者：西达本胺联合紫杉醇和卡铂治疗晚期非小细胞肺癌的Ⅱ期临床试验, objectType=article, longId=56007, objectId=47375600e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47375600e5b, replyNumber=0, likeNumber=71, createdTime=2015-09-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47375600e5b, moduleTitle=招募患者：西达本胺联合紫杉醇和卡铂治疗晚期非小细胞肺癌的Ⅱ期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47375600e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1396273, encodeId=7ac713962e3a2, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, objectTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, objectType=article, longId=37047, objectId=6eb73e0471c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eb73e0471c, replyNumber=0, likeNumber=36, createdTime=2014-06-27, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eb73e0471c, moduleTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eb73e0471c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡铂

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Natl Cancer Inst：TNBC：新辅助蛋白结合型紫杉醇+卡铂vs蛋白结合型紫杉醇+吉西他滨

2018-07-14

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌

2018-06-03

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

2018-05-05

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

CLIN CANCER RES：新辅助卡铂和多西他赛治疗的三阴性乳腺癌患者的病理缓解情况

2018-04-27

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：卡铂-紫杉醇 vs 卡铂-紫杉醇-曲妥珠单抗治疗子宫浆液性癌

2018-03-30

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lung Cancer：氨柔比星/卡铂+培非格司亭治疗广泛期SCLC

2018-02-16

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验

2017-12-22

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

PLos One：使用顺铂 vs.卡铂治疗肺癌的血栓栓塞风险比较

2017-12-14

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。

2017-11-27

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：伊匹单抗联合紫杉醇和卡铂治疗晚期非小细胞肺癌

2017-09-02

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）

2017-06-23

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J CLIN ONCOL：Palifosfamide联合卡铂或依托泊苷治疗小细胞肺癌的效果研究

2017-06-17

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：帕利伐米加入卡铂联合依托泊苷治疗中不能改善转移性小细胞肺癌患者的生存

2017-06-17

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

J Clin Oncol：精原细胞瘤复发----卡铂辅助治疗疗效如何？

2017-04-13

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：男性临床I期精原细胞癌卡铂辅助化疗后复发状况调查

2016-12-02

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS

2016-10-13

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

JCO：伊立替康+顺铂 vs 紫杉醇+卡铂一线治疗卵巢透明细胞癌(JGOG3017/GCIG 试验III期)

2016-07-26

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好

2016-07-10

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

招募患者：西达本胺联合紫杉醇和卡铂治疗晚期非小细胞肺癌的Ⅱ期临床试验

2015-09-11

智者为医08 (审核中...)

前往app查看评论内容

#卡铂#

Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验

2014-06-27

科室
- - 订阅+
  - 更多科室
工具
服务